Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

Ovarian Cancer Clinical Trial

— VIPIDO  

Official title:

Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04891185
• Other study ID #: S65525
• Secondary ID: 2021-002449-13
• Status: Terminated
• Phase: Phase 2
• Start date: October 1, 2021
• Est. completion date: October 1, 2023

Study information

• Verified date: May 2023
• Source: Universitaire Ziekenhuizen KU Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Visualise peritoneal lesions of epithelial ovarian cancer (EOC) in both primary and interval debulking surgery by using intravascular indocyanine green (ICG) and near-infrared (NIR) light. This Trial wants to investigate whether ICG can increase the visibility of peritoneal lesions and can differentiate between peritoneal implants and fibrosis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: October 1, 2023
• Est. primary completion date: October 1, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.

2. At least 18 years of age.

3. Advanced stage epithelial ovarian cancer: FIGO stage IIIb, IIIc or IV. (For FIGO staging classification, please refer to Appendix 7).

4. A biopsy or cytology confirming the presence of high-grade serous epithelial ovarian carcinoma

5. Preoperative imaging (CT and/or MRI), describing metastatic implants, as standard of care.

Exclusion Criteria:

1. Participant has a history of following diseases:

1. Hyperthyroidism

2. Autonomously functioning thyroid adenoma

2. Participant has an allergy or hypersensitivity for one or more of the following

components:

1. Iodine (including potassium iodine)

2. Indocyanine green

3. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.

4. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.

5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device during the surgery itself.

6. Participant has a severe renal impairment (classified as renal function<30 ml/min/1,73m2 according to CKD-EPI).

7. Participant utilises sodium bisulfite-containing heparin preparations during the day

before surgery. For Belgian registered drugs, this contains:

1. Danaparoid (Orgaran®)

2. Other low-molecular weight heparins registered in Belgium do not contain sodium bisulfite and are not an exclusion criterion.

8. Participants requires thyroid scintigraphy utilising radioactive iodine one week after surgery.

9. A previous history of major intra-abdominal surgery with potentially major adhesions and/or distorted anatomy.

10. Participants utilises one of the interacting drugs listed in the protocol

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• Indocyanine green
Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection

Locations

Country	Name	City	State
Belgium	Universitaire Ziekenhuizen Leuven	Leuven

Sponsors (1)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen KU Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of correct visualisation during debulking surgery with the near-infrared (NIR) fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.		During debulking surgery
Secondary	Rate of diagnostic accuracy during debulking surgery with the NIR fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.		During debulking surgery
Secondary	Percentage of lesions with positive correlation between pre-operative radiographic examination(s) and the ICG signal in vivo with the NIR fluorescence camera during surgery and immediately after surgery with the pathological examination.		During debulking surgery and immediately after debulking surgery, when the pathological examination report is available.
Secondary	Obtaining the tumour-to-background ratio of fluorescence in peritoneal lesions, lymph nodes and other anatomical structures during debulking surgery by utilising still images captures with the NIR fluorescence camera.		During debulking surgery
Secondary	Assessment of the number and type of adverse effects, severe adverse effects and adverse reactions with the trial dose of the IMP during and immediately after the surgery.		During debulking surgery and immediately after the surgery, up to the point in time when the pathological report is available.